METABOLISM

1.8 Billion (39%) of all adults are overweight or obese

Obesity reduces lifespan by an average of 3 years and severe obesity reduces it by 8-10 years

Poor diet quality and physical inactivity contributed to approximately 17% of U.S. deaths in 2000

Nearly 75% of US adults will be overweight or obese by 2035

Direct healthcare costs of obesity and associated chronic diseases $480 billion (21% of medical spending)

Cost of diseases due to obesity in U.S. $1.72 trillion (9.3% GDP)

Excessive weight accounts for 47% of costs for chronic diseases in the U.S.

Indirect work loss costs of obesity and associate chronic diseases $1.24 trillion in the U.S. 

The weight loss and weight management diet market was valued at $192 billion in 2019 and is projected to reach $295 billion by 2027, registering a CAGR of 7.0% from 2021 to 2027

Currently, Semaglutide (Wegovy, GLP-1 agonist) is the only effective weight reduction therapy on the market

In Q3 2022 alone, Wegovy sales were $2.9 billion

Our therapy would be a first-in-class competitor with a broader range of benefits